Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

day 35 after the injection of microplasmin or placebo, whether they had a vitrectomy or not. In patients who received the highest dose of microplasmin there was an improvement in vision (6.9 more letters read on a standard eye chart compared to a baseline reading prior to treatment); this compares with a 0.1 letter improvement for the placebo group.

Microplasmin in Stroke

In late September, the Company announced promising results from its MITI IV Phase II trial to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients. The overall results of the study were presented by Dr. Vincent Thijs on September 27 at the World Stroke Congress in Vienna.

The MITI IV (Microplasmin In Treatment of Ischemic stroke - IntraVenous) trial was a Phase II, multicentre, randomized, double-blinded, placebo-controlled, ascending-dose clinical trial evaluating the safety and preliminary efficacy of the intravenous administration of microplasmin in 40 patients, 4 to 12 hours after onset of acute ischemic stroke

The study found that microplasmin was generally well tolerated with no evidence of increased bleeding risk; there were no systemic bleeding events reported and there was no evidence of increased rate of bleeding in general, in those patients that had been treated with microplasmin compared to those treated with placebo.

In addition, the study provided some interesting preliminary efficacy results. Approximately 25% of patients treated with microplasmin had reperfusion (restoration of blood flow) within eight hours of being treated, this compares with 10% of placebo-treated patients. Moreover, of the patients who had more severe vascular blockages, 33% of patients treated with microplasmin achieved reperfusion compared with 14% of placebo-treated patients. Due to the small number of patients in this study, neither of these endpoints were statistically significant. However, the study also s
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Texas , May 29, 2015  Caris ... from two studies in which researchers utilized Caris ... service, to identify potential therapeutic targets in patients ... expression of the programmed cell death protein 1 ... on June 1 at the 2015 American Society ...
(Date:5/29/2015)... Results from a Phase III clinical trial examining ... reduce the size of melanoma tumors in patients injected ... of Clinical Oncology. , The global, randomized trial ... melanoma, a potentially fatal form of skin cancer. The ... safety and efficacy of the oncolytic virus immunotherapy compared ...
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of Jain PharmaBiotech,s ... Technologies, Markets, and Companies" to their ... This report deals with therapeutic ... at improving patient care by monitoring drug ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ) has announced the addition ... Testing services - Global Forecast to 2020" report ... market is estimated to be worth around $2.5 billion ... during the forecast period of 2014 to 2020 ... protein consumption, increasing adoption of advanced genetic technologies for ...
Breaking Biology Technology:Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Global Therapeutic Drug Monitoring Market 2015-2024 2Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2
... by the Elderly and Patients With Movement Disorders at ... May 18 Millions of people in the US ... walk. For many of them, traditional walking aids such ... being able to walk normally and live independently.Now there,s ...
... 18 /PRNewswire-Asia/ -- Global biomedical sciences companies,invested more ... 2008. This rides on,Singapore,s strong scientific fundamentals, with ... , The continued confidence ... as companies look to the fast growing Asian,market ...
... paper published,today in the online edition of Nature Genetics, ... colleagues from Iceland, Denmark and the,Netherlands present the discovery ... genome (SNPs) that influence the age of girls at ... influenced by both genetic,and environmental factors, though the SNPs ...
Cached Biology Technology:Now Available: State-of-the-Art Gait Training Device to Help Millions Walk More Normally Again 2Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 2Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 3Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 4Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 5deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease 2deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease 3deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease 4
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3
... the genes necessary to function as an antibody-producing B cell, ... important immune-system cells. James Hagman, PhD, Professor of Immunology at ... motors" that work in opposing directions to control the development ... the online version of The Proceedings of the ...
... the early evolution of the estrogen receptor, research by a ... Medicine may lead to a contraceptive for female lampreys ... Great Lakes region of the United States. This ... aggressively consume trout, salmon, sturgeon and other game fish. ...
... game that has taken the world by storm with its ability ... fast-changing world of genome sequencing and the field of medical genetics, ... Spring Harbor Laboratory (CSHL). The report will be published as the ... Genome Research . Combining a 2,000-year-old Chinese math theorem ...
Cached Biology News:Pushmi-pullyu of B-cell development discovered 2Evolution of a contraceptive for sea lamprey 2CSHL scientists harness logic of 'Sudoku' math puzzle to vastly enhance genome-sequencing capability 2CSHL scientists harness logic of 'Sudoku' math puzzle to vastly enhance genome-sequencing capability 3
...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Recombinant Mouse sTNF RII/TNFRSF1B...
Biology Products: